Inhibrx Biosciences (INBX) Accumulated Expenses: 2023-2025
Historic Accumulated Expenses for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $27.0 million.
- Inhibrx Biosciences' Accumulated Expenses fell 9.79% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year decrease of 9.79%. This contributed to the annual value of $29.9 million for FY2024, which is 30.96% down from last year.
- As of Q3 2025, Inhibrx Biosciences' Accumulated Expenses stood at $27.0 million, which was down 5.32% from $28.5 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Accumulated Expenses registered a high of $43.3 million during Q4 2023, and its lowest value of $23.9 million during Q2 2024.
- Moreover, its 3-year median value for Accumulated Expenses was $29.9 million (2024), whereas its average is $30.7 million.
- In the last 5 years, Inhibrx Biosciences' Accumulated Expenses slumped by 30.96% in 2024 and then grew by 19.35% in 2025.
- Quarterly analysis of 3 years shows Inhibrx Biosciences' Accumulated Expenses stood at $43.3 million in 2023, then crashed by 30.96% to $29.9 million in 2024, then declined by 9.79% to $27.0 million in 2025.
- Its Accumulated Expenses stands at $27.0 million for Q3 2025, versus $28.5 million for Q2 2025 and $32.8 million for Q1 2025.